N-Propyl-1,4-diamino-2-butene

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Propyl-1,4-diamino-2-butene
• 英文别名: (E)-N'-propylbut-2-ene-1,4-diamine
• 化学式: C₇H₁₆N₂
• 分子量: 128.22
• InChiKey: CVFHKCAAFFOCPM-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Multifunctional curing agents and their use in improving strength of composites containing carbon fibers embedded in polymeric matrix
  申请人：UT-Battelle, LLC

  公开号：US10240011B2

  公开（公告）日：2019-03-26

  A functionalized carbon fiber having covalently bound on its surface a sizing agent containing epoxy groups, at least some of which are engaged in covalent bonds with crosslinking molecules, wherein each of said crosslinking molecules possesses at least two epoxy-reactive groups and at least one free functional group reactive with functional groups of a polymer matrix in which the carbon fiber is to be incorporated, wherein at least a portion of said cros slinking molecules are engaged, via at least two of their epoxy-reactive groups, in crosslinking bonds between at least two epoxy groups of the sizing agent. Composites comprised of these functionalized carbon fibers embedded in a polymeric matrix are also described. Methods for producing the functionalized carbon fibers and composites thereof are also described.

  一种功能化碳纤维，其表面共价结合了一种含有环氧基团的上浆剂，其中至少有一部分与交联分子以共价键结合，其中每个交联分子都具有至少两个环氧反应基团和至少一个与碳纤维所结合的聚合物基体的官能团反应的自由官能团、其中，至少有一部分所述交联分子通过至少两个环氧反应基团参与上浆剂的至少两个环氧基团之间的交联键。此外，还介绍了由嵌入聚合物基体中的这些功能化碳纤维组成的复合材料。此外，还介绍了生产功能化碳纤维及其复合材料的方法。
• Ansamycins having improved pharmacological and biological properties
  申请人：Zhang Lin

  公开号：US20050267122A1

  公开（公告）日：2005-12-01

  Ansamycins and methods of preparing and using the same are described. At least some of these ansamycins exhibit one or more of improved aqueous formulation ability, chemical stability, and bioavailability. Some of the derivatives described are dimers. These and others described can include one or more solubilizing groups that have expected merit in rendering the overall compounds useful as drugs and prodrugs.

  介绍了ansamycins及其制备和使用方法。这些ansamycins 中至少有一些表现出一种或多种改进的水溶液配制能力、化学稳定性和生物利用度。所述的一些衍生物是二聚体。这些衍生物和其他衍生物可包括一个或多个增溶基团，这些基团在使整个化合物成为有用的药物和原药方面具有预期的优点。
• Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors
  申请人：Fritz Lawrence

  公开号：US20060079493A1

  公开（公告）日：2006-04-13

  The invention relates generally to methods of treating cell proliferative diseases with HSP90 inhibitors and, depending on the specific aspect and embodiment(s) claimed, to the treatment of proliferative diseases that are associated with fusion proteins, e.g., bcrabl, or mutant proteins or cellular protein isoforms, e.g., mutant forms of p53.

  本发明一般涉及用HSP90抑制剂治疗细胞增殖性疾病的方法，并根据所要求的具体方面和实施方案，涉及与融合蛋白（如bcrabl）或突变蛋白或细胞蛋白异构体（如p53的突变形式）有关的增殖性疾病的治疗。
• METHODS FOR TREATING GENETICALLY-DEFINED PROLIFERATIVE DISORDERS WITH HSP90 INHIBITORS
  申请人：Conforma Therapeutic Corporation

  公开号：EP1423080A2

  公开（公告）日：2004-06-02
• EP1423080A4
  申请人：——

  公开号：EP1423080A4

  公开（公告）日：2009-06-03